User profiles for "author:Robin Parihar"
Robin PariharAssistant Professor of Pediatrics, Division of Hematology/Oncology, Baylor College of … Verified email at bcm.edu Cited by 2836 |
Myeloid-derived suppressor cells in the tumor microenvironment
M Dysthe, R Parihar - Tumor Microenvironment: Hematopoietic Cells–Part …, 2020 - Springer
Myeloid-derived suppressor cells (MDSCs) represent a heterogenous population of
immature myeloid cells capable of modulating immune responses. In the context of cancer …
immature myeloid cells capable of modulating immune responses. In the context of cancer …
[HTML][HTML] IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
R Parihar, J Dierksheide, Y Hu… - The Journal of clinical …, 2002 - Am Soc Clin Investig
The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors
has generally been considered to result from direct antiproliferative effects, the induction of …
has generally been considered to result from direct antiproliferative effects, the induction of …
Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells
Successful adoptive T-cell immunotherapy of solid tumors will require improved expansion
and cytotoxicity of tumor-directed T cells within tumors. Providing recombinant or transgenic …
and cytotoxicity of tumor-directed T cells within tumors. Providing recombinant or transgenic …
NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors
Solid tumors are refractory to cellular immunotherapies in part because they contain
suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that …
suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that …
Natural killer cells produce T cell–recruiting chemokines in response to antibody-coated tumor cells
In the current report, we have examined the ability of natural killer (NK) cells to produce T
cell–recruiting chemokines following dual stimulation with interleukin (IL)-2 or IL-12 and …
cell–recruiting chemokines following dual stimulation with interleukin (IL)-2 or IL-12 and …
Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells
Abstract The Her2/neu (c‐erbB‐2) oncogene encodes a 185‐kDa protein tyrosine kinase
which is overexpressed in 20% of breast adenocarcinomas and is recognized by a …
which is overexpressed in 20% of breast adenocarcinomas and is recognized by a …
[HTML][HTML] The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse
GB Lesinski, M Anghelina, J Zimmerer… - The Journal of …, 2003 - Am Soc Clin Investig
IFN-α activates the signal transducer and activator of transcription (STAT) family of proteins;
however, it is unknown whether IFN-α exerts its antitumor actions primarily through a direct …
however, it is unknown whether IFN-α exerts its antitumor actions primarily through a direct …
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells
Bacterial DNA contains a high frequency of unmethylated CpG motifs that stimulate immune
cells via TLR9. NK cells express a low-affinity activating receptor for the Fc portion of IgG …
cells via TLR9. NK cells express a low-affinity activating receptor for the Fc portion of IgG …
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
AC Jaime-Ramirez, BL Mundy-Bosse… - The Journal of …, 2011 - journals.aai.org
The antitumor effects of therapeutic mAbs may depend on immune effector cells that express
FcRs for IgG. IL-12 is a cytokine that stimulates IFN-γ production from NK cells and T cells …
FcRs for IgG. IL-12 is a cytokine that stimulates IFN-γ production from NK cells and T cells …
[HTML][HTML] Design and implementation of NK cell-based immunotherapy to overcome the solid tumor microenvironment
Simple Summary Cell therapy over the last few years has revolutionized the treatment of
blood cancers. However, efficacy against cancers of solid organs remains limited. These …
blood cancers. However, efficacy against cancers of solid organs remains limited. These …